Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2017

01-07-2017 | Review Article

Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib

Authors: Varinder Kaur, Arjun Swami

Published in: Annals of Hematology | Issue 7/2017

Login to get access

Abstract

Bruton’s tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naïve, heavily pre-treated, and high-risk CLL/SLL. With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase. As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged. New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets. Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL. We provide a comprehensive analysis of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge.
Literature
1.
Pazdur R. New drug application approval—Imbruvica (Department of Health and Human Services. Food and Drug administration). Ref ID 3395788; 2013
2.
IMBRUVICA US Prescribing information, March 2016
3.
4.
Vetrie D, Vorechovsky I, Sideras P et al (1993) The gene involved in X-linked agammaglobulinaemia is a member of src family of protein tyrosine kinases. Nature 361:226–233CrossRefPubMed
5.
Rawlings DJ, Saffran DC, Tsukada S et al (1993) Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science 261(5119):358–361CrossRefPubMed
6.
Herishanu Y, Pérez-Galán P, Liu D et al (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563–574CrossRefPubMedPubMedCentral
7.
Duhren von-Minden M, Ubelhart R, Schneider D et al (2012) Chronic lymphocytic leukemia is driven by antigen-independent cell-autonomous signaling. Nature 489:309–312CrossRefPubMed
8.
9.
10.
11.
Cheng S, Guo A, Lu P et al (2014) BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 28:649–657CrossRefPubMed
12.
13.
Chen SS, Chang BY, Chang S (2016) BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30(4):833–843CrossRefPubMed
14.
Arana E, Harwood NE, Batista FD (2008) Regulation of integrin activation through the B-cell receptor. J Cell Sci 121(pt 14):2279–2286CrossRefPubMed
15.
Spaargaren M, Beuling EA, Rurup ML et al (2003) The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 198(10):1539–1550CrossRefPubMedPubMedCentral
16.
de Gorter DJ, Beuling EA, Kersseboom R et al (2007) Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26(1):93–104CrossRefPubMed
17.
Herman SEM, Gordon AL, Hertlein E et al (2011) Bruton tyrosine kinase represents as promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287–6296CrossRefPubMedPubMedCentral
18.
Ponader S, Chen SS, Buggy JJ et al (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182–1189CrossRefPubMedPubMedCentral
19.
Honigberg LA, Smith AM, Sirisawad M et al (2010) The Bruton’s tyrosine kinase inhibitor PCI-32765 block B cell activation and is efficacious in models of auto-immune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107(29):13075–13080CrossRefPubMedPubMedCentral
20.
Burger JA, Buggy JJ (2013) Emerging drug profiles: Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385–2391CrossRefPubMed
21.
Herman SEM, McAuley EM, Wong DH et al (2015) Ibrutinib inhibits both T-cell receptor and toll-like receptor signaling in chronic lymphocytic leukemia. Blood 125(23):313
22.
23.
24.
Byrd JC, Furman RR, Coutre SE et al (2015) Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutnib. Blood 125(16):2479–2506CrossRef
25.
O’Brien S, Furman RR, Coutre SE et al (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1B/2 trial. Lancet Oncol. 15(1):48–58. doi:10.​1016/​S1470-2045(13)70513-8 CrossRefPubMed
26.
Farooqui MZ, Valdex J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymhocytic leukemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16(2):169–176CrossRefPubMed
27.
Byrd JC, Brown JR, O’Brien S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371(3):213–223CrossRefPubMedPubMedCentral
28.
Burger JA, Tedeschi A, Barr PM et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437CrossRefPubMedPubMedCentral
29.
Sun C, Tian X, Lee YS et al (2015) Partial reconstitution of humoral immunity with fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 126(19):2213–2219CrossRefPubMedPubMedCentral
30.
Brown JR, Barrientos JC, Barr PM et al (2015) The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 125:2915–2922CrossRefPubMedPubMedCentral
31.
Chanan-Khan A, Cramer P, Demirkan F et al (2016) Ibrutiib combined with bendamustine and rituximab compared with placebo, bendamustine and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomized, double-blind, phase 3 study. Lancet Oncol 17(2):200–211CrossRefPubMed
32.
Burger JA, Keating MJ, Wierda WG et al (2014) Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15:1090–1099CrossRefPubMedPubMedCentral
33.
Jaglowski SM, Jones JA, Nagar V et al (2015) Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1B/2 study. Blood 126:842–850CrossRefPubMedPubMedCentral
34.
Levade M, David E, Garcia C et al (2014) Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet function. Blood 124(26):3991–3995CrossRefPubMed
35.
Lipsky AH, Farooqui MZH, Tian X et al (2015) Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Hematologica 100(12):1572–1578CrossRef
36.
Mato AR, Islam P, Daniel C et al (2016) Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood 127(8):1064–1067CrossRefPubMed
37.
Klien BEK, Klein R, Lee KE et al (2008) Incidence of age-related cataract over a 15-year interval: the Beaver Dam Eye Study. Ophthalmology 115:477–482CrossRef
38.
Kaur V, Mehta P, Johnsurd J et al (2014) Tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood 124(23):3503–3505CrossRefPubMed
39.
Maddocks K, Ruppert AS, Lozanski G et al (2015) Etiology of ibrutinib discontinuation and outcomes in chronic lymphocytic leukemia patients. JAMA Oncol 1(1):80–87CrossRefPubMedPubMedCentral
40.
41.
42.
Burger JA, Landau DA, Taylor-Weiner A et al (2016) Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 7:11589CrossRefPubMedPubMedCentral
43.
Thompson PA et al (2015) Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121:3612–3621CrossRefPubMedPubMedCentral
44.
Cheng S, Guo A, Lu P et al (2015) Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 29(4):895–900CrossRefPubMed
45.
Liu TM, Woyach JA, Zhong Y et al (2015) Hypomorphic mutation of phospholipase C, y2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cel receptor activation. Blood 126(1):61–68CrossRefPubMedPubMedCentral
46.
Rubio-Moscardo F et al (2005) Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor agents. Blood 106:3214–3222CrossRefPubMed
47.
Cosson A, Chapiro E, Lambert J, et al. (2015) The Gain of short arm of chromosome 2 (2p+) induces XPO1 overexpression and drug resistance in chronic lymphocytic leukemia. Blood 126: abstract 492
48.
Senapedis WT, Baloglu E, Landesman Y (2014) Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol 27C:74–86CrossRef
49.
Fornerod M, van Baal S, Valentine V et al (1997) Chromosomal localization of genes encoding CAN/Nup214-interacting proteins—human CRM1 localizes to 2p16, whereas Nup88 localizes to 17p13 and is physically linked to SF2p32. Genomics 42(3):538–540CrossRefPubMed
50.
Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110CrossRefPubMed
51.
Jain P, Keating M, Wierda W et al (2015) Outcomes of patients with chronic lymphocytic leukemia after discontinuation of ibrutinib. Blood 125(13):2062–2067CrossRefPubMedPubMedCentral
52.
Gardner HL, Harrington BK, Izumi R, et al. ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. American Association for Cancer Research Annual Meeting, San Diego, CA, April 5–9, 2014. abstract
53.
Byrd JC, Harrington B, O’Brien S et al (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):323–332CrossRefPubMed
54.
Blunt MD, Parnell J, Larrayoz M et al (2015) The SYK/JAK inhibitor cerdulatinib (PRT062070) shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing B cell receptor and microenvironment signaling. Blood 126(23):1716
55.
Seymore JF, Davis MS, Pagel JM, et al. (2014) ABT-199 (GDC-0199) in relapsed/refractor (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control. J Clin Oncol 32(5s):abstract 7015
56.
Deng J, Isik E, Farnandez S et al (2015) Ibrutinib therapy increases BCL-2 dependence and enhances sensitivity to venetoclax in CLL. Blood 126(23):490
57.
Jones JA, Wierda WG, Choi MY, et al. (2016) Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. J Clin Oncol 34(suppl; abstr 7519)
58.
Roberts AW, Ma S, Brander DM et al. Determination of recommended phase 2 dose of ABT- 199 (GDC-0199) combined with Rituximab 9R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL_. Blood 2014; Abstract 325
59.
Stilgenbauer S, Eichhorst B, Schetelig J et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicenter, open-label, phase 2 study. Lancet Oncol 17(6):768–778CrossRefPubMed
60.
Chiron D, Di Liberto M, Martin P et al (2014) Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4(9):1022–1035CrossRefPubMedPubMedCentral
61.
Porcu P, Flinn I, Kahl BS, et al. (2014) Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase d, y inhibitor in patients previously treated with ibrutinib. Blood 124(21): abstract 3335
62.
Dong S, Guinn D, Dubovksy JA et al (2014) IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124(24):3583–3586CrossRefPubMedPubMedCentral
63.
Hing ZA, Mantel R, Beckwith KA et al (2015) Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic lymphoma. Blood 125(20):3128–3132CrossRefPubMedPubMedCentral
64.
Hing ZA, Fung HY, Ranganathan P et al (2016) Next generation XOP1 inhibitor shows improved efficacy and invivo tolerability in hematologic malignancies. Leukemia 30(12):2364–2372CrossRefPubMedPubMedCentral
65.
Thijssen R, Burg J, Garrick B et al (2016) Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood 128(4):574–583CrossRefPubMed
66.
Kuo H, Crowley R, Xue L, et al. (2014) Combination of ibrutinib and BCL-2 or SYK inhibitors in ibrutinib resistant ABC-subtype of diffuse large B-cell lymphoma. Blood 124(21): abstract 505
Metadata
Title
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Authors
Varinder Kaur
Arjun Swami
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-2973-2

Other articles of this Issue 7/2017

Annals of Hematology 7/2017 Go to the issue

Original Article

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

Letter to the Editor

Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma: methodological issues to avoid misinterpretation

Letter to the Editor

Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine

Original Article

Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin

Original Article

Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography

Erratum

Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits